ACTR-53. MGMT PROMOTER METHYLATION ANALYSIS FOR ALLOCATING COMBINED CCNU/TMZ CHEMOTHERAPY: LESSONS LEARNED FROM THE CeTeG/NOA-09 TRIAL

BACKGROUND: The CeTeG/NOA-09 trial recently showed a survival benefit for combination chemotherapy with CCNU/TMZ in glioblastoma patients with a methylated MGMT promoter as determined by quantitative Methylation-Specific PCR (qMSP). Identifying patient subgroups with a pronounced benefit from this n...

詳細記述

保存先:
書誌詳細
出版年:Neuro Oncol
主要な著者: Tzaridis, Theophilos, Schäfer, Niklas, Weller, Johannes, Steinbach, Joachim, Seidel, Sabine, Schlegel, Uwe, Sabel, Michael, Hau, Peter, Seidel, Clemens, Krex, Dietmar, Goldbrunner, Roland, Tonn, Joerg-Christian, Grauer, Oliver, Schaub, Christina, Coch, Christoph, Glas, Martin, Pietsch, Torsten, Fimmers, Rolf, Reifenberger, Guido, Felsberg, Jörg, Herrlinger, Ulrich
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2019
主題:
Adult Clinical Trials - Non-Immunologic
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847379/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.095
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料